Sponsors (6)
The bill improves early warning and government visibility into drug supply chains—helping patients, providers, and emergency preparedness—but does so at the cost of added compliance burdens for manufacturers and risks to proprietary data, which could prompt withholding and undermine effectiveness.
Patients with chronic conditions, hospitals, and clinicians receive earlier, broader shortage warnings and actionable supply information so they can seek alternatives or plan care.
State and federal regulators and health systems gain more timely, regular supplier data (biannual reports plus voluntary off-cycle updates), improving supply‑chain visibility for oversight and response.
Improved early notice about demand spikes, export restrictions, or supplier concentration strengthens public‑health preparedness and response during declared emergencies.
Drug manufacturers face increased compliance burdens and costs to collect and submit detailed API, supplier, and volume information, which may be especially heavy for smaller firms.
Requiring and potentially releasing supplier legal names, volumes, and API-source details risks exposing sensitive commercial or security information, which could cause competitive harm and discourage full disclosure.
Firms may withhold, delay, or underreport information—citing timing, burden, or confidentiality—which would reduce the effectiveness of the reporting system and leave some shortages unaddressed.
Based on analysis of 3 sections of legislative text.
Introduced August 1, 2025 by Amy Klobuchar · Last progress August 1, 2025
Requires drug manufacturers and registrants to give the Department of Health and Human Services earlier and more detailed warnings about permanent discontinuances, interruptions, and other events (including spikes in demand or export restrictions) that could meaningfully disrupt supplies of certain critical human drugs. It also tightens the definition of which drugs are covered, and requires registrants to submit biannual supplier reports listing API and input suppliers and the amounts of drug made from each supplier's inputs.